Syncom Formulations (India) Limited

SYNCOMF

INE312C01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:17:58 07/06/2024 BST			5-day change	1st Jan Change
12.03 ^INR	-0.17%		+0.42%	-20.01%

05-17	Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
05-17	Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Syncom Formulations India Ltd. Announces Board Changes

July 18, 2012 at 01:47 pm

Syncom Formulations India Ltd. announced resignation of Shri. Sanjay Mehta, the Independent Director and Appointment of Shri. Praveen Jindal as an Independent Director effective July 12, 2012.

Latest news about Syncom Formulations (India) Limited

Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-17	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-17	CI
Syncom Formulations Limited Announces Board Changes	03-29	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Syncom Formulations Begins Commercial Production at Expanded Plant in Pithampur, India	22/08/23	MT
Syncom Formulations Limited Commences Commercial Production	21/08/23	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Syncom Formulations Limited Announces Commercial Production Starts from 30 June 2023	01/07/23	CI
Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/05/23	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/05/23	CI
Syncom Formulations Limited Announces Executive Changes	02/05/23	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Syncom Formulations Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022	20/09/22	CI
Syncom Formulations Sees Delay in Completion of Expansion Project	16/09/22	MT
Syncom Formulations Limited Announces Updates on its Project for Expansion Cum Modernisation of Existing Plant at Pithampur	15/09/22	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/08/22	CI
Syncom Formulations Limited Appoints Ruchi Jindal as an Additional Director	28/06/22	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Syncom Formulations Limited Announces Executive Changes	13/11/21	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/11/21	CI
Syncom Formulations India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/06/21	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21	CI
Syncom Formulations Limited announced that it has received INR 100.787496 million in funding	24/01/21	CI

Chart Syncom Formulations (India) Limited

Duration

Period

Chart Syncom Formulations (India) Limited

More charts

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYNCOM FORMULATIONS (INDIA) LIMITED	-20.01%	135M
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B

Other Pharmaceuticals

Syncom Formulations (India) Limited

Equities

SYNCOMF

INE312C01025

Pharmaceuticals

Syncom Formulations India Ltd. Announces Board Changes

Latest news about Syncom Formulations (India) Limited

Chart Syncom Formulations (India) Limited

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals